Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 5/20 | 0.51 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.41 |
| ▸ | BCR | P11274 | 9/20 | 0.41 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | CBLB | Q13191 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533111 | 0.86 | GPR142 (0.54) | GPR142DHX9ABL1BCRBRAF | |
| SCHEMBL3535368 | 0.81 | BRAF (0.52) | BRAF | |
| SCHEMBL3527702 | 0.79 | GPR142 (0.40) | GPR142BRAF | |
| SCHEMBL3529710 | 0.79 | BRAF (0.41) | GPR142BRAF | |
| SCHEMBL3532512 | 0.77 | GPR142 (0.55) | GPR142DHX9ABL1BCRBRAF | |
| SCHEMBL4031152 | 0.70 | BRAF (0.43) | GPR142BRAF | |
| SCHEMBL21615098 | 0.68 | GPR142 (1.00) | GPR142ABL1BCRBRAF | |
| SCHEMBL3529616 | 0.68 | BRAF (0.51) | BRAF | |
| SCHEMBL4031666 | 0.68 | BRAF (0.49) | BRAF | |
| SCHEMBL3535198 | 0.67 | BRAF (0.40) | GPR142BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858804-B2 | Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137815-A1 | Process for Making Cytokine Inhibiting Compounds Containing 4- and 5-Imidazolyl Rings and the Intermediates Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137815-A1 | Process for Making Cytokine Inhibiting Compounds Containing 4- and 5-Imidazolyl Rings and the Intermediates Thereof | MIF, IL4, IL4I1 | GPR142 3493/4885DHX9 2593/4885ABL1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.